Literature DB >> 11859277

Early cardiovascular involvement in patients with systemic sclerosis (SSc).

Jerzy Wranicz1, Marzenna Zielińska, Iwona Cygankiewicz, Bozena Dziankowska-Bartkowiak, Anna Sysa-Jedrzejowska.   

Abstract

BACKGROUND: Systemic sclerosis (SSc) is a connective tissue disease characterized by progressive fibrosis of the skin, and by distinctive forms of internal organ involvement. Symptoms usually occur relatively late and are nonspecific, thus often unrecognized. The purpose of our study was to evaluate cardiac function in patients with SSc by means of non-invasive methods in order to detect early dysfunction of the cardiovascular system. MATERIAL/
METHODS: A group of 22 patients with SSc was compared with a group of 22 healthy volunteers. Standard EKG, 24-hour Holter monitoring (HM), and echocardiography were performed in all subjects.
RESULTS: In patients with SSc, HM revealed a tendency to tachycardia. Conduction disturbances were observed in 3 patients. In 6 patients significant ventricular arrhythmia was found. Silent ischemia episodes were detected in 6 patients. In HRV analysis, significantly lower values were detected in patients with SSc than in controls. LPs were present in one patient with SSc, and none in the control group. The mean values for QT interval did not exceed the range of normal values. No signs of systolic cardiac dysfunction were detected, while in 6 patients left ventricle diastolic dysfunction was recognized. Valvular lesions were observed in 8 patients, but only in 2 patients were they hemodynamically important.
CONCLUSIONS: 24-hour Holter monitoring and echocardiography enable the early detection of cardiovascular dysfunction in patients with systemic sclerosis presenting without apparent cardiac impairment symptoms.

Entities:  

Mesh:

Year:  2002        PMID: 11859277

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  7 in total

1.  Implantable cardioverter defibrillator to prevent sudden cardiac death in a patient with systemic sclerosis: A clinical case.

Authors:  Fabio Marsico; Gianluigi Savarese; Celestino Sardu; Cristoforo D'Ascia; Donatella Ruggiero; Laura Casaretti; Valentina Parisi; Francesca Musella; Elisabetta Pirozzi; Roberto Formisano; Teresa Losco; Pasquale Perrone Filardi
Journal:  J Cardiol Cases       Date:  2012-03-31

2.  Electrocardiographic evaluation in patients with systemic scleroderma and without clinically evident heart disease.

Authors:  Anna Biełous-Wilk; Małgorzata Poreba; Edyta Staniszewska-Marszałek; Rafał Poreba; Maciej Podgórski; Dariusz Kałka; Dariusz Jagielski; Lesław Rusiecki; Witold Pilecki; Eugeniusz Baran; Ryszard Andrzejak; Małgorzata Sobieszczańska
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-07       Impact factor: 1.468

Review 3.  The heart in systemic sclerosis.

Authors:  Virginia Steen
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

Review 4.  The autonomic nervous system in systemic sclerosis. A review.

Authors:  Luca Bertinotti; Stefania Bracci; Francesca Nacci; Nicola Colangelo; Angela Del Rosso; Roberto Casale; Alberto Pignone; Marco Matucci-Cerinic
Journal:  Clin Rheumatol       Date:  2003-12-10       Impact factor: 2.980

5.  Transcutaneous electrical nerve stimulation (TENS) improves upper GI symptoms and balances the sympathovagal activity in scleroderma patients.

Authors:  Hanaa Sallam; Terry A McNearney; Dipti Doshi; J D Z Chen
Journal:  Dig Dis Sci       Date:  2007-03-20       Impact factor: 3.487

Review 6.  Cardiovascular Imaging for Systemic Sclerosis Monitoring and Management.

Authors:  Peter Glynn; Sarah Hale; Tasmeen Hussain; Benjamin H Freed
Journal:  Front Cardiovasc Med       Date:  2022-03-31

7.  Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients.

Authors:  Bozena Dziankowska-Bartkowiak; Elzbieta Waszczykowska; Anna Zalewska; Anna Sysa-Jedrzejowska
Journal:  Mediators Inflamm       Date:  2005-08-14       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.